Loading…
Perspective Therapeutics, Inc. is projected to rise to $3.31 by 2027, a +14% move from its current price of $2.91. CATX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.82 | $2.91 | $3.00 | +0.02% |
| Aug 4 | $2.78 | $2.91 | $3.04 | +0.04% |
| Aug 5 | $2.76 | $2.91 | $3.08 | +0.06% |
| Aug 6 | $2.73 | $2.91 | $3.10 | +0.07% |
| Aug 7 | $2.71 | $2.91 | $3.13 | +0.09% |
| Aug 8 | $2.70 | $2.91 | $3.15 | +0.11% |
| Aug 9 | $2.68 | $2.91 | $3.17 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.68 | $2.91 | $3.17 | +0.13% |
| Week 2 | $2.59 | $2.92 | $3.28 | +0.26% |
| Week 3 | $2.53 | $2.92 | $3.38 | +0.39% |
| Week 4 | $2.48 | $2.93 | $3.46 | +0.52% |
| Week 5 | $2.43 | $2.93 | $3.53 | +0.64% |
| Week 6 | $2.39 | $2.93 | $3.60 | +0.77% |
| Week 7 | $2.35 | $2.94 | $3.66 | +0.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
It pursues VMT-a-NET in Phase 1/2a clinical trials for unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy. VMT01 is in Phase 1/2a for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359 is a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a beta-emitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.
It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc.
in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Perspective Therapeutics, Inc. trades under the symbol CATX. The current price is $2.92 and the market capitalization is $333.01M, with a rank of 3193.
The stock’s price outlook, based on a year-by-year forecast, suggests a gradual upside over time. The 2026 average price is $2.92, with higher forecasts into the late 2020s and beyond, culminating in a 2050 average price of $12.55 and a maximum of $26.65.
This path reflects anticipated upside from 2028 onward, with 2030, 2040, and 2050 averages of $4.48, $5.23, and $12.55 respectively, and maximums up to $7.03, $9.95, and $26.65 respectively.
A major floor 20.6% below — a decisive break under it would weaken the trend.
The nearest floor, 3.1% below — buyers have tended to step in here.
The nearest ceiling, 24.7% above — a clean break opens room to run.
A major ceiling 61.9% above — clearing it would confirm fresh momentum.
Key CATX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CATX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.89 | Buy | $2.92 | Sell |
| MA 10 | $2.92 | Sell | $2.94 | Sell |
| MA 20 | $3.05 | Sell | $3.02 | Sell |
| MA 50 | $3.24 | Sell | $3.25 | Sell |
| MA 100 | $3.77 | Sell | $3.49 | Sell |
| MA 200 | $3.54 | Sell | $3.67 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.66 | Neutral |
| Stoch RSI (14) | 52.27 | Neutral |
| CCI (20) | -61.24 | Neutral |
| Williams %R (14) | -77.50 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -9.63 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 22.50 | Neutral |
| TRIX (15) | -0.45 | Sell |
| Awesome (5,34) | -0.20 | Sell |
| Ultimate (7,14,28) | 42.92 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 2.91 | Sell |
| ADX (14) | 18.53 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is bearish overall. RSI(14) is 40, indicating modest downside momentum.
Key moving averages show SMA50 at $3.39 and SMA200 at $3.58, suggesting near-term resistance above the current price.
Support is at $2.92 and resistance at $3.63, framing a tight range around the current price. The 30-day range extends from $2.27 to $3.76, highlighting limited volatility in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.33 | $2.91 | $3.92 | 0% | Neutral | |
| $2.60 | $3.31 | $4.47 | +14% | Neutral | |
| $2.82 | $3.71 | $5.23 | +27% | Bullish | |
| $3.07 | $4.15 | $6.05 | +43% | Bullish | |
| $3.30 | $4.57 | $6.85 | +57% | Bullish | |
| $3.05 | $4.32 | $6.63 | +48% | Bullish | |
| $2.92 | $4.22 | $6.61 | +45% | Bullish | |
| $3.04 | $4.48 | $7.15 | +54% | Bullish | |
| $3.03 | $4.55 | $7.39 | +56% | Bullish | |
| $3.69 | $5.63 | $9.32 | +94% | Bullish | |
| $3.57 | $5.92 | $10.48 | +103% | Bullish | |
| $7.10 | $13.60 | $26.57 | +367% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.33 | $2.91 | $3.53 | +0.00% |
| September 2026 | $2.53 | $3.01 | $3.69 | +3.38% |
| October 2026 | $2.47 | $2.96 | $3.67 | -1.64% |
| November 2026 | $2.45 | $2.95 | $3.70 | -0.27% |
| December 2026 | $2.56 | $3.10 | $3.92 | +5.18% |
Click any year to see its month-by-month CATX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Perspective Therapeutics, Inc.'s 2026 outlook centres on $2.91, within a $2.33 to $3.92 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CATX could reach as high as $4.47, with a base case around $3.31 and support toward $2.60 — roughly +14% from $2.91. Price action looks broadly range-bound.
Expect CATX to range from $2.82 to $5.23 through 2028. The $3.71 average target implies a +27% move from current prices. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CATX price prediction for 2029 points to an average of $4.15 (low $3.07, high $6.05) — a potential gain of +43% on today's $2.91. Momentum favours further upside here.
In 2030, CATX is projected to trade between $3.30 and $6.85, averaging $4.57 — a potential gain of +57% from today's $2.91. That is up +10% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Perspective Therapeutics, Inc.'s 2031 outlook centres on $4.32, within a $3.05 to $6.63 range. That is -6% versus the projected 2030 average. That marks a +48% change versus current levels. Momentum favours further upside here.
By 2032, CATX could reach as high as $6.61, with a base case around $4.22 and support toward $2.92 — roughly +45% from $2.91. Buyers look set to stay in control over this stretch.
Expect CATX to range from $3.04 to $7.15 through 2033. The $4.48 average target implies a +54% move from current prices. That is up +6% on the projected 2032 average. Momentum favours further upside here.
The CATX price prediction for 2034 points to an average of $4.55 (low $3.03, high $7.39) — a potential gain of +56% on today's $2.91. Buyers look set to stay in control over this stretch.
In 2035, CATX is projected to trade between $3.69 and $9.32, averaging $5.63 — a potential gain of +94% from today's $2.91. That is up +24% on the projected 2034 average. Momentum favours further upside here.
Perspective Therapeutics, Inc.'s 2040 outlook centres on $5.92, within a $3.57 to $10.48 range. That is up +5% on the projected 2035 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CATX could reach as high as $26.57, with a base case around $13.60 and support toward $7.10 — roughly +367% from $2.91. Momentum favours further upside here.
Investing $1,000 in CATX today (≈ 343.642612 CATX) could be worth
$4,671.91
+$3,671.91 (+367%) by 2050 · US Dollar
Based on the average projected CATX price of $13.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CATXwould be worth at today's price.
$1,000 invested in CATX on Jul 31, 2025 (≈ 260.416672 CATX) would be worth
$757.81
-$242.19 (-24.2%) today · 0.76× · US Dollar
Based on a CATX entry price of $3.84 vs. today's $2.91.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.91 | $1,000 | -0.0% |
| 1 month ago | $3.46 | $841.04 | -15.9% |
| 3 months ago | $3.85 | $755.84 | -24.4% |
| 6 months ago | $5.06 | $575.1 | -42.5% |
| 1 year ago | $3.84 | $757.81 | -24.2% |
| All time (5.0y) ago | $6.8 | $427.94 | -57.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CATX forecast.
Our base-case forecast reaches $5.80 around 2040.
Implied market cap at $5.80: $661.47M
The multi-year forecast depicts a bullish trajectory after a mixed start, with 2026 at an average of $2.92 and 2027 at $3.14, then rising through 2028 ($3.62) and 2029 ($4.15) toward higher levels.
Notably, 2030 shows an average of $4.48 with a return-on-investment of 53.3%, followed by continued gains into the 2030s. By 2040, the forecast projects an average of $5.23 with an ROI of 79.2%, and by 2050 the average is $12.55 with an ROI of 329.9%.
In 2035 the forecast envisions an average of $5.21 with a max of $9.17 and an ROI of 78.6%. The 2050 projection also lists a max of $26.65, underscoring substantial upside potential while acknowledging substantial uncertainty and risk in long-term markets.
These figures imply a path to higher values over time, but they are estimates and not guarantees; actual results will depend on a range of market and clinical development factors.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $4.48 with a max of $7.03 and a min of $3.09, and an ROI of 53.3% with a bullish sentiment.
The 2026 forecast is neutral with an average of $2.92. From 2028 onward, the outlook is bullish with higher averages and notable upside by 2030, 2040, and 2050 (for example 2030 avg $4.48, ROI 53.3%; 2040 avg $5.23, ROI 79.2%; 2050 avg $12.55, ROI 329.9%). These are estimates, not guarantees.
Yes, the max forecast price reaches $26.65 by 2050, with earlier years like 2035 max $9.17 and 2040 max $9.95, indicating that reaching $10 is possible by 2050 according to the forecast.
The current price is $2.92 and the market capitalization is $333.01M.
Healthcare.
Perspective Therapeutics, Inc. Community Discussion
0Share your Perspective Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.